Craig Burd

Assistant Professor


Research Interests

Steroid hormones act through a family of transcription factors that are able to initiate genetic programs associated with virtually all aspects of physiology.  Receptors respond to steroid binding by initiating a cascade of events leading to the activation or repression of target genes.  These genetic programs are tightly regulated through various steps of this activation process including receptor localization, DNA binding, cofactor binding, and chromatin reorganization.  These mechanisms of control are frequently deregulated in cancers, most notably breast and prostate.  My group focuses on the molecular mechanisms governing the control of receptor specificity and identifying the changes that occur in disease states.

A particular interest of my group is the potential of environmental compounds known as endocrine disruptors to influence estrogen receptor activity.  Both man-made, industrial chemicals, such as bisphenol A, and naturally occurring plant compounds are able to bind and activate the estrogen receptor in a manner similar to the canonical ligand, estradiol.  Nonetheless, activation of the receptor by these alternative ligands results in different transcriptional programs.  One aim of my group is to dissect the mechanistic differences of activation by these ligands with the hope of better assessing the risk of exposure.

A second area of interest involves epigenetic changes that occur during windows of susceptibility.  Exposure to environmental compounds at specific life stages results in increased risk of developing a growing assortment of physiological disorders.  The pathology associated with these compounds usually present well after the exposure and suggests permanent and epigenetic alteration to the affected tissues.  My group is interested in understanding the mechanistic pathways by which environmental compounds may initiate epigenetic changes in the breast that lead to altered morphology and an increased risk of breast cancer.  


 Burd, CJ Figure 1


Laboratory Personnel

Ali Shapiro  Ali Shapiro
  Research Assistant




Andrea Patterson

  Andrea Patterson
  Graduate Student






Craig Burd PubMed

  • Burd CJ, Archer TK. Chromatinarchitecture defines the glucocorticoid response. Mol Cell Endocrinol. 2013 Mar 29. doi:pii: S0303-7207(13)00116-0. 10.1016/j.mce.2013.03.020. [Epub ahead of print] PubMed PMID: 23545159.

  • Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013 Jan 2;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21. PubMed PMID: 23257359; PubMed Central PMCID: PMC3533295

  • Burd CJ, Ward JM, Crusselle-Davis VJ, Kissling GE, Phadke D, Shah RR, Archer TK: Analysis of Chromatin Dynamics during Glucocorticoid Receptor Activation. Mol Cell Biol 2012;32:1805-1817. PMID: 22451486

  • Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE: Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 2011;286:8117-8127. PMID:  21212260

  • Burd CJ, Kinyamu HK, Miller FW, Archer TK: UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008;283:34976-34982. PMID: 18922793

  • Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES: Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008;68:5628-5638. PMID: 18632615

  • Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE: Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene 2008;27:3111-3121. PMID: 18084330

  • Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE: Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 2006;103:2190-2195. PMID: 16461912

  • Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE: A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 2005;24:431-444. PMID: 15558026

  • Link KA, Burd CJ, Williams E, Marshall T, Rosson G, Henry E, Weissman B, Knudsen KE: BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol 2005;25:2200-2215. PMID: 15743818

  • Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE: Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol 2005;19:607-620. PMID: 15539430

  • Singleton DW, Feng Y, Burd CJ, Khan SA: Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology 2003;144:121-128.PMID: 12488337

Areas of Expertise
  • Transcriptional regulation
  • Chromatin and epigenetics
  • Steroid hormone receptors
  • Endocrine disrupting compounds

Picture for burd.7

(614) 688-7458
614 688-4245
590 Biomedical Research Tower
460 West 12th Avenue
Columbus, OH 43210